Fewer adverse events leading to dose interruptions or reductions ( @ -LSB- @ % -RSB- of @ patients vs @ -LSB- @ % -RSB- of @ ) or treatment discontinuation ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) occurred in patients in the @ mg group than in the @ mg group .